- Home
- SLS vs PALI Comparison
SLS vs PALI Comparison
Compare SLS & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | PALI |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 240.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLS | PALI |
|---|---|---|
| Price | $3.61 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 5.6M | 4.6M |
| Earning Date | 03-19-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.53 |
| 52 Week High | $5.18 | $2.64 |
Technical Indicators
Market Signals| Indicator | SLS | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 49.72 |
| Support Level | $3.46 | $1.65 |
| Resistance Level | $3.90 | $1.84 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 4.96 | 77.50 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.